Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 19, 2019

Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate

Boehringer Ingelheim has signed a new collaboration and licence agreement with Bridge Biotherapeutics to develop autotaxin inhibitor BBT-877 to treat patients with fibrosing interstitial lung diseases.

Image: Boehringer Ingelheim headquarters in Ingelheim, Germany. Photo: courtesy of Boehringer Ingelheim.